The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Treatment With a Monocyte-Targeting Agent for Pancreatic Cancer

Andrea Wang-Gillam, MD, PhD
Published Online: 5:32 PM, Mon January 19, 2015
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.

More on this trial > >

<<< Back to the Gastrointestinal Cancers Symposium conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.